Effectiveness and safety of sumatriptan 85 mg/naproxen sodium 500 mg combination for acute migraine: prospective real-world evidence from the GRASP Study Group.
- DOI
- 10.3389/fneur.2026.1912200
- Published
- 2026
- Container
- Frontiers in neurology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fneur.2026.1912200,
title = {Effectiveness and safety of sumatriptan 85 mg/naproxen sodium 500 mg combination for acute migraine: prospective real-world evidence from the GRASP Study Group.},
author = {Rikos D and Argyriou AA and Dermitzakis EV and Soldatos P and Dimisianos N and Tsironis C and Mavraki E and Chondrogianni M and Foska A and Dimitriadou E and Giakoumakis E and Vikelis M and Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group},
year = {2026},
journal = {Frontiers in neurology},
doi = {10.3389/fneur.2026.1912200},
url = {https://doi.org/10.3389/fneur.2026.1912200}
}RIS
TY - JOUR TI - Effectiveness and safety of sumatriptan 85 mg/naproxen sodium 500 mg combination for acute migraine: prospective real-world evidence from the GRASP Study Group. AU - Rikos D AU - Argyriou AA AU - Dermitzakis EV AU - Soldatos P AU - Dimisianos N AU - Tsironis C AU - Mavraki E AU - Chondrogianni M AU - Foska A AU - Dimitriadou E AU - Giakoumakis E AU - Vikelis M AU - Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group PY - 2026 JO - Frontiers in neurology DO - 10.3389/fneur.2026.1912200 UR - https://doi.org/10.3389/fneur.2026.1912200 ER -
APA
D, R., AA, A., EV, D., P, S., N, D., C, T., E, M., M, C., A, F., E, D., E, G., M, V., & Group, G. R. A. F. T. S. O. H. A. P. (. S. (2026). Effectiveness and safety of sumatriptan 85 mg/naproxen sodium 500 mg combination for acute migraine: prospective real-world evidence from the GRASP Study Group.. Frontiers in neurology. https://doi.org/10.3389/fneur.2026.1912200
Source records
- pubmed · retrieved 2026-09-25T18:21:40.585Z